7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 
      
    		                                           
      assets
    		                                           
      current assets:
    		                                           
      cash and cash equivalents
    		100,376,000 33,880,000 37,940,000 26,676,000 50,347,000 43,915,000 195,579,000 55,516,000 37,185,000 69,519,000 18,362,000 36,632,000 29,408,000 16,226,000 12,454,000 26,371,000 11,264,000 8,829,000 16,805,000 29,117,000 3,870,000 18,790,000 15,260,000 8,377,000 30,952,000 19,123,000 14,343,000 24,779,000 169,506,000 34,610,000 36,356,000 8,988,478 2,568,063 3,393,651 4,359,046 3,075,502 3,054,892 5,159,930 3,958,763 768,550 2,140,115 9,497,200  
      short-term investments – available-for-sale
    		614,194,000 773,844,000 813,918,000 875,936,000 880,093,000 898,348,000 767,397,000 306,563,000 339,056,000 323,401,000 117,302,000                                 
      prepaid clinical trial and preclinical study costs
    		21,891,000 16,478,000 13,300,000 3,476,000 4,476,000 3,323,000 2,716,000 2,624,000 4,389,000 5,491,000 9,878,000 8,144,000 9,167,000 9,859,000 8,012,000 7,806,000 7,235,000 8,254,000 7,559,000 7,276,000 7,120,000 6,702,000 6,738,000 7,458,000 612,000 343,000 168,000 335,000 1,847,000 1,499,000 1,014,000             
      prepaid expenses and other current assets
    		2,242,000 2,815,000 865,000 1,128,000 1,733,000 138,000 643,000 2,522,000 670,000 960,000 3,926,000 3,411,000 956,000 1,087,000 388,000 619,000 915,000 1,150,000 625,000 442,000 710,000 914,000 547,000 405,000 572,000 665,000 251,000 278,000 607,000 593,000 249,000 388,969 340,121 447,932 177,451 824,269 1,005,471 1,113,696 909,895 1,097,599 1,442,629 610,198 33,391 
      total current assets
    		738,703,000 827,017,000 866,023,000 907,216,000 936,649,000 945,724,000 966,335,000 367,225,000 381,300,000 399,371,000 149,468,000 167,040,000 165,146,000 179,863,000 193,299,000 210,528,000 224,285,000 237,662,000 249,863,000 256,104,000 263,134,000 270,618,000 276,446,000 283,501,000 289,256,000 293,644,000 299,137,000 302,133,000 306,616,000 144,258,000 78,731,000 21,851,798 11,525,074 14,264,002 14,673,917 13,974,829 15,623,313 18,310,165 12,161,521 15,201,648 18,932,251 22,269,649 360,398 
      right-of-use assets
    		666,000 780,000 892,000 1,003,000 1,113,000 977,000 1,052,000 1,126,000 1,200,000 1,273,000 1,346,000 1,418,000 1,489,000 1,560,000 1,632,000 25,000 101,000 176,000 249,000 321,000 392,000 462,000 530,000 598,000 664,000 730,000 794,000                 
      deferred financing costs
    		 8,000 32,000 56,000 80,000 105,000 98,000 106,000 130,000 16,000 48,000 38,000 15,000 52,000 64,000  88,000 7,000 27,000                         
      deposits
    		46,000 46,000 46,000 46,000 46,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000 33,000    29,000 29,000 29,000 29,000 29,000 29,000 29,000 29,000 29,000     39,341 39,341 39,341 39,341 80,000 80,000 80,000 80,000    
      total assets
    		739,415,000 827,851,000 866,993,000 908,321,000 937,888,000 946,839,000 967,518,000 368,490,000 382,663,000 400,693,000 150,895,000 168,529,000 166,683,000 181,508,000 195,028,000 210,662,000 224,474,000 237,845,000 250,139,000 256,502,000 263,623,000 271,198,000 277,104,000 284,256,000 290,122,000 294,493,000 300,080,000 302,312,000 306,796,000 144,468,000 78,971,000 22,121,411 11,839,444 14,320,911 15,152,607 14,535,708 16,317,693 18,549,007 12,756,902 15,439,103 19,012,251 22,269,649 2,769,322 
      liabilities and stockholders’ equity
    		                                           
      current liabilities:
    		                                           
      accounts payable
    		4,413,000 5,494,000 7,702,000 9,813,000 254,000 11,090,000 5,225,000 7,512,000 5,711,000 5,611,000 3,799,000 8,529,000 3,142,000 6,104,000 3,119,000 1,444,000 2,852,000 4,210,000 4,848,000 3,988,000 2,756,000 3,209,000 3,098,000 2,431,000 2,095,000 1,870,000 1,676,000 959,000 1,215,000 1,493,000 658,000 1,529,935 1,555,472 1,304,711 1,726,824 1,203,888 881,311 1,206,384 1,172,351 592,414 401,672 1,008,277 1,879,414 
      other accrued liabilities
    		21,217,000 26,018,000 11,373,000 17,111,000 24,951,000 13,669,000 27,220,000 11,299,000 7,375,000 7,553,000 11,541,000 13,114,000 10,620,000 8,522,000 7,999,000 7,305,000 8,386,000 8,463,000 7,789,000 7,811,000 6,636,000 5,528,000 5,135,000 4,044,000 3,802,000 3,468,000 2,961,000 3,591,000 3,528,000 2,612,000 1,889,000 2,256,543 2,837,392 2,418,355 1,655,342 1,237,122 996,437 852,744 745,774 1,384,398 1,103,432 119,647 517,892 
      lease liability, current
    		437,000 468,000 498,000 489,000 480,000 334,000 329,000 324,000 319,000 314,000 309,000 304,000 299,000 238,000 150,000 29,000 115,000 198,000 279,000 330,000 323,000 316,000 309,000 302,000 295,000 288,000 281,000                 
      total current liabilities
    		26,067,000 31,980,000 19,573,000 27,413,000 25,685,000 25,093,000 32,774,000 19,135,000 13,405,000 13,478,000 15,649,000 21,947,000 14,061,000 14,864,000 11,268,000 8,778,000 11,353,000 12,871,000 12,916,000 12,129,000 9,715,000 9,053,000 8,542,000 6,777,000 6,192,000 5,626,000 4,918,000 4,550,000 4,743,000 4,105,000 6,339,000 8,656,575 9,613,483 7,726,978 3,382,166 6,476,534 6,077,692 5,738,892 1,918,125 1,976,812 5,722,551 4,876,110 27,708,696 
      lease liability, net of current portion
    		318,000 410,000 502,000 630,000 755,000 766,000 852,000 936,000 1,018,000 1,100,000 1,181,000 1,260,000 1,337,000 1,414,000 1,490,000     29,000 115,000 198,000 279,000 360,000 438,000 513,000 588,000                 
      total long-term liabilities
    		318,000 410,000 502,000 630,000 755,000 766,000 852,000 936,000 1,018,000 1,100,000 1,181,000 1,260,000 1,337,000 1,414,000 1,490,000     29,000 115,000 198,000 279,000 360,000 438,000 513,000 588,000 12,000      6,054 4,224,354 16,307 20,476 24,646 5,069,038 4,737,293 19,149  2,899,669 
      total liabilities
    		26,385,000 32,390,000 20,075,000 28,043,000 26,440,000 25,859,000 33,626,000 20,071,000 14,423,000 14,578,000 16,830,000 23,207,000 15,398,000 16,278,000 12,758,000 8,778,000 11,353,000 12,871,000 12,916,000 12,158,000 9,830,000 9,251,000 8,821,000 7,137,000 6,630,000 6,139,000 5,506,000 4,562,000 4,743,000 4,105,000 6,339,000 8,656,575 9,613,483 7,733,032 7,606,520 6,492,841 6,098,168 5,763,538 6,987,163 6,714,105 5,741,700 4,876,110 30,608,365 
      commitments and contingencies
    		                                           
      stockholders’ equity:
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2025 and december 31, 2024; no shares issued and outstanding at september 30, 2025 and december 31, 2024
    		                                           
      common stock
    		1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 358 285 277 239 208 199 193 97 97 98 98 60 
      treasury stock
    		       -6,795,000 -6,795,000 -6,795,000 -6,795,000 -6,795,000 -6,795,000 -6,795,000 -5,121,000                             
      additional paid-in capital
    		1,402,539,000 1,394,723,000 1,380,669,000 1,368,972,000 1,362,305,000 1,350,801,000 1,340,789,000 733,546,000 729,278,000 724,754,000 453,057,000 445,267,000 432,330,000 430,390,000 428,086,000 425,614,000 424,116,000 422,745,000 419,528,000 412,589,000 411,082,000 409,569,000 407,478,000 405,803,000 404,581,000 403,630,000 402,464,000 401,090,000 399,847,000 231,587,000 157,146,000 94,339,179 78,999,693 77,264,402 73,052,514 68,326,818 66,858,121 65,617,288 54,902,270 54,277,716 53,729,783 53,123,840 13,769 
      accumulated deficit
    		-689,884,000 -599,097,000 -533,536,000 -487,907,000 -452,490,000 -427,550,000 -405,299,000 -377,944,000 -353,339,000 -330,805,000 -311,580,000 -292,049,000 -272,490,000 -256,717,000 -239,285,000 -223,182,000 -210,826,000 -197,583,000 -182,202,000 -168,192,000 -157,244,000 -147,956,000 -138,384,000 -128,697,000 -121,247,000 -115,516,000 -107,842,000 -102,918,000 -97,678,000 -91,078,000 -84,406,000 -80,854,932 -76,770,459 -70,670,801 -65,499,167 -60,277,267 -56,632,658 -52,825,226 -49,132,433 -45,545,445 -40,454,482 -35,717,938 -27,852,872 
      accumulated other comprehensive loss
    		374,000 -166,000 -216,000 -788,000 1,632,000 -2,272,000 -1,599,000 -389,000 -905,000 -1,040,000 -618,000  -1,761,000 -1,649,000 -1,411,000 -549,000 -170,000 -189,000 -104,000        -49,000 -423,000 -117,000 -147,000 -109,000 -19,769 -3,558 -5,999 -7,499 -6,892 -6,137 -6,786 -195 -7,370 -4,848 -12,461  
      total stockholders’ equity
    		713,030,000 795,461,000 846,918,000 880,278,000 911,448,000 920,980,000 933,892,000 348,419,000 368,240,000 386,115,000 134,065,000 145,322,000 151,285,000 165,230,000 182,270,000 201,884,000 213,121,000 224,974,000 237,223,000 244,344,000 253,793,000 261,947,000 268,283,000 277,119,000 283,492,000 288,354,000 294,574,000 297,750,000 302,053,000 140,363,000 72,632,000 13,464,836 2,225,961 6,587,879 7,546,087 8,042,867 10,219,525 12,785,469 5,769,739 8,724,998 13,270,551 17,393,539  
      total liabilities and stockholders’ equity
    		739,415,000 827,851,000 866,993,000 908,321,000 937,888,000 946,839,000 967,518,000 368,490,000 382,663,000 400,693,000 150,895,000 168,529,000 166,683,000 181,508,000 195,028,000 210,662,000 224,474,000 237,845,000 250,139,000 256,502,000 263,623,000 271,198,000 277,104,000 284,256,000 290,122,000 294,493,000 300,080,000 302,312,000 306,796,000 144,468,000 78,971,000 22,121,411 11,839,444 14,320,911 15,152,607 14,535,708 16,317,693 18,549,007 12,756,902 15,439,103 19,012,251   
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2025 and december 31, 2024; no shares issued and outstanding at june 30, 2025 and december 31, 2024
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2025 and december 31, 2024; no shares issued and outstanding at march 31, 2025 and december 31, 2024
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2024 and 2023; no shares issued and outstanding at december 31, 2024 and 2023
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2024 and december 31, 2023; no shares issued and outstanding at september 30, 2024 and december 31, 2023
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2024 and december 31, 2023; no shares issued and outstanding at june 30, 2024 and december 31, 2023
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2024 and december 31, 2023; no shares issued and outstanding at march 31, 2024 and december 31, 2023
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2023 and 2022; no shares issued and outstanding at december 31, 2023 and 2022
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2023 and december 31, 2022; no shares issued and outstanding at september 30, 2023 and december 31, 2022
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2023 and december 31, 2022; no shares issued and outstanding at june 30, 2023 and december 31, 2022
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2023 and december 31, 2022; no shares issued and outstanding at march 31, 2023 and december 31, 2022
    		                                           
      short-term investments – available for sale
    		           118,853,000 125,615,000 152,691,000 172,445,000 175,732,000 204,871,000 219,429,000 224,874,000 219,269,000 251,434,000 244,212,000 253,901,000 267,261,000 257,120,000 273,513,000 284,375,000 276,741,000 134,656,000 107,556,000 41,112,000 11,587,478 7,270,719 8,689,630 7,954,240 10,075,058 11,562,950 12,036,539 7,292,863 13,335,499 15,349,507 12,162,251  
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2022 and 2021; no shares issued and outstanding at december 31, 2022 and 2021
    		                                           
      accumulated other comprehensive income
    		           -1,102,000        -54,000 -46,000 333,000 -812,000 12,000 157,000 239,000                  
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2022 and december 31, 2021; no shares issued and outstanding at september 30, 2022 and december 31, 2021
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2022 and december 31, 2021; no shares issued and outstanding at june 30, 2022 and december 31, 2021
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2022 and december 31, 2021; no shares issued and outstanding at march 31, 2022 and december 31, 2021
    		                                           
      deferred public offering and other financing costs
    		               76,000    48,000 68,000 89,000 99,000 128,000 173,000 90,000 120,000 150,000 180,000 210,000 240,000 269,613 275,029 17,568 439,349 521,538 614,380       
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2021 and 2020; no shares issued and outstanding at december 31, 2021 and 2020
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2021 and december 31, 2020; no shares issued and outstanding at september 30, 2021 and december 31, 2020
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2021 and december 31, 2020; no shares issued and outstanding at june 30, 2021 and december 31, 2020
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2021 and december 31, 2020; no shares issued and outstanding at march 31, 2021 and december 31, 2020
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2020 and 2019; no shares issued and outstanding at december 31, 2020 and 2019
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2020 and december 31, 2019; no shares issued and outstanding at september 30, 2020 and december 31, 2019
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2020 and december 31, 2019; no shares issued and outstanding at june 30, 2020 and december 31, 2019
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2020 and december 31, 2019; no shares issued and outstanding at march 31, 2020 and december 31, 2019
    		                                           
      liabilities, convertible notes and stockholders’ equity
    		                                           
      deferred rent
    		                           12,000      6,054 10,862 16,307 20,476 24,646 27,624 31,239 19,149   
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2019 and 2018; no shares issued and outstanding at december 31, 2019 and 2018
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2019 and december 31, 2018; no shares issued and outstanding at september 30, 2019 and december 31, 2018
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2019 and december 31, 2018; no shares issued and outstanding at june 30, 2019 and december 31, 2018
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2019 and december 31, 2018; no shares issued and outstanding at march 31, 2019 and december 31, 2018
    		                                           
      accrued interest
    		                               21,960    34,894     152,361 121,111 112,475 
      convertible notes payable, current portion
    		                               3,450,540    3,269,582     1,911,024 1,670,509 310,350 
      debt conversion feature liability
    		                               1,397,597   453,350 731,048   1,698,671  2,154,062 1,956,566 62,191 
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2018 and 2017; no shares issued and outstanding at december 31, 2018 and 2017
    		                                           
      accrued interest, current
    		                              34,000  9,982 59,333   22,674 10,455      
      convertible notes payable, current
    		                              3,721,000  3,180,411 3,050,427   2,826,135 2,382,688      
      debt conversion feature liability, current
    		                              37,000  2,030,226 894,152   1,351,135 1,286,621      
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2018 and december 31, 2017; no shares issued and outstanding at september 30, 2018 and december 31, 2017
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2018 and december 31, 2017; no shares issued and outstanding at june 30, 2018 and december 31, 2017
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2018 and december 31, 2017; no shares issued and outstanding at march 31, 2018 and december 31, 2017
    		                                           
      prepaid clinical trial costs
    		                               886,873 1,346,171 1,732,789 2,183,180         
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2017 and 2016; no shares issued and outstanding at december 31, 2017 and 2016
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2017 and december 31, 2016; no shares issued and outstanding at september 30, 2017 and december 31, 2016
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2017 and december 31, 2016; no shares issued and outstanding at june 30, 2017 and december 31, 2016
    		                                           
      accrued interest, non-current
    		                                  47,113    202,882 183,611    
      convertible notes payable
    		                                  3,713,029    3,139,861 2,151,540   1,429,993 
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2017 and december 31, 2016; no shares issued and outstanding at march 31, 2017 and december 31, 2016
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2016 and 2015; no shares issued and outstanding at december 31, 2016 and 2015
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2016 and december 31, 2015; no shares issued and outstanding at september 30, 2016 and december 31, 2015
    		                                           
      deferred public offering financing costs
    		                                     158,842 515,381 157,455    
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2016 and december 31, 2015; no shares issued and outstanding at june 30, 2016 and december 31, 2015
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2016 and december 31, 2015; no shares issued and outstanding at march 31, 2016 and december 31, 2015
    		                                           
      accrued license fees
    		                                          24,826,374 
      stockholders’ equity
    		                                           
      preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2015 and no shares authorized at december 31, 2014; no shares issued and outstanding at december 31, 2015 and 2014
    		                                           
      deferred ipo financing costs
    		                                          2,408,149 
      other assets
    		                                        80,000  775 
      total liabilities and stockholders’ deficit
    		                                         22,269,649 2,769,322 
      cash
    		                                          327,007 
      liabilities, convertible notes and stockholders’ deficit
    		                                           
      stockholders’ deficit:
    		                                           
      total stockholders’ deficit
    		                                          -27,839,043 
      revenues
    		                                           
      operating expenses:
    		                                           
      research and development
    		                                          138,969 
      general and administrative
    		                                          322,071 
      total operating expenses
    		                                          461,040 
      income from operations
    		                                          -461,040 
      other incomes:
    		                                           
      change in fair value of accrued license fees
    		                                          4,960,511 
      change in fair value of debt conversion feature liability
    		                                          82,656 
      amortization of debt discount
    		                                          171,955 
      interest expense
    		                                          35,253 
      total other incomes
    		                                          5,250,375 
      net income
    		                                          -5,711,415 
      basic and diluted net income per share
    		                                          -1.4 
      weighted-average shares used for eps calculation
    		                                          4,073,609 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.